Although the majority of patients with acute myeloid leukemia (AML) treated with intensive
chemotherapy achieve a complete remission (CR), many are destined to relapse if treated …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Mutations of the nucleophosmin (NPM1) gene, encoding for a nucleolar multifunctional
protein, occur in approximately one-third of adult acute myeloid leukemia (AML). NPM1 …

DDX41 germline mutations (DDX41MutGL) are the most common genetic predisposition to
myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that …

To design a simple and reproducible classifier predicting the overall survival (OS) of patients
with acute myeloid leukemia (AML)≥ 60 years of age treated with 7+ 3, we sequenced 37 …

Li et al delineate a novel technique for assessing measurable residual disease (MRD) by
the assessment of isolated leukemia stem cells (LSCs). They report that assessment of MRD …

Acute myeloid leukemia (AML) is one of the malignant hematological cancers with high
mortality. Finding a more effective and readily available treatment is of the utmost …

In patients with isocitrate dehydrogenase (IDH)–mutated acute myeloid leukemia (AML)
treated by intensive chemotherapy (IC), prognostic significance of co-occurring genetic …

For most patients with acute myeloid leukemia (AML), an allogeneic hematopoietic stem cell
transplantation (HSCT) offers the highest chance of cure. Recently, the European …

Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …